The skin cancer test developer reported total revenues of $14.8 million compared to $3.7 in Q3 2018, beating the Wall Street expectation of $9.5 million.
The pilot study with the Mayo Clinic is the final step before SkylineDx commences a US trial next year for its molecular test for primary cutaneous melanoma.
The researchers said that they have demonstrated an approach that skirts a bottleneck and enables building pathology support systems from large datasets.
Using genetic information from cancer cells, SkylineDx is developing its test to predict whether a patient is at risk of having metastases in the lymph nodes,
Skin cancer apps can supplement but not substitute standard medical care, and they require proper vetting using standard validation methods, researchers said.
